Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

INTERNEURON's BUCINDOLOL ENTERING NIH/V-A SPONSORED CHF STUDY

Executive Summary

INTERNEURON's BUCINDOLOL ENTERING NIH/V-A SPONSORED CHF STUDY involving 3,000 patients set to begin "in late 1994/early 1995," the company said June 22. The Beta-blocker Evaluation of Survival Trial (BEST) will randomize parents to two arms: one receiving placebo plus the current "standard of care" for congestive heart failure (angiotensin-converting enzyme inhibitors when tolerated, diuretics and digoxin), and the other receiving standard care plus bucindolol. The primary endpoint of the study will be mortality. The National Institutes of Health said the study will take five years and will enroll mostly non-Department of Veterans Affairs patients.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024679

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel